全文获取类型
收费全文 | 40809篇 |
免费 | 3174篇 |
国内免费 | 149篇 |
学科分类
医药卫生 | 44132篇 |
出版年
2021年 | 824篇 |
2020年 | 475篇 |
2019年 | 775篇 |
2018年 | 897篇 |
2017年 | 622篇 |
2016年 | 667篇 |
2015年 | 752篇 |
2014年 | 1030篇 |
2013年 | 1424篇 |
2012年 | 1924篇 |
2011年 | 2061篇 |
2010年 | 1207篇 |
2009年 | 1070篇 |
2008年 | 1817篇 |
2007年 | 1893篇 |
2006年 | 1861篇 |
2005年 | 1780篇 |
2004年 | 1732篇 |
2003年 | 1565篇 |
2002年 | 1557篇 |
2001年 | 1260篇 |
2000年 | 1301篇 |
1999年 | 1100篇 |
1998年 | 437篇 |
1997年 | 366篇 |
1996年 | 326篇 |
1995年 | 334篇 |
1994年 | 319篇 |
1993年 | 336篇 |
1992年 | 917篇 |
1991年 | 850篇 |
1990年 | 722篇 |
1989年 | 766篇 |
1988年 | 713篇 |
1987年 | 739篇 |
1986年 | 683篇 |
1985年 | 700篇 |
1984年 | 557篇 |
1983年 | 483篇 |
1982年 | 311篇 |
1980年 | 267篇 |
1979年 | 467篇 |
1978年 | 313篇 |
1977年 | 272篇 |
1976年 | 280篇 |
1975年 | 277篇 |
1974年 | 308篇 |
1973年 | 306篇 |
1972年 | 275篇 |
1971年 | 268篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
1.
Noreen M. Walsh Heinz Kutzner Luis Requena Lorenzo Cerroni 《Journal of cutaneous pathology》2019,46(9):698-708
We review the spectrum of cutaneous disorders associated with inflammatory and neoplastic plasmacytic pathology. Because plasma cells are derived from B‐lymphocytes our overview includes discussion of certain lymphoplasmacytic proliferations. It is structured along histopathological lines, addressing conditions characterized by (a) cutaneous plasma cell infiltrates, (b) deposits of plasma cell products or their derivatives in the skin and (c) miscellaneous, poorly understood cutaneous complications of plasmacytic disorders. Lesions arising primarily in the skin and those due to cutaneous involvement by multisystem disorders are addressed. The range includes a spectrum of tumefactive and circulatory manifestations. We highlight key clinical and pathological features of the different conditions and outline recent advances in our understanding of these entities. By emphasizing the dermatopathological characteristics of this spectrum of disorders we hope to hone the diagnostic accuracy of practitioners in the field. 相似文献
2.
3.
4.
5.
Cost‐Effectiveness and Cost‐Utility Analysis of Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome: Results From the PRECISE Study 下载免费PDF全文
Furio Zucco MD Roberta Ciampichini MSc Angelo Lavano MD Amedeo Costantini MD Marisa De Rose MD Paolo Poli MD Gianpaolo Fortini MD Laura Demartini MD Enrico De Simone MD Valentino Menardo MD Piero Cisotto MD Mario Meglio MD Luciana Scalone PhD Lorenzo G. Mantovani DSc 《Neuromodulation》2015,18(4):266-276
6.
Nicole D. Facompre Pavithra Rajagopalan Varun Sahu Alexander T. Pearson Kathleen T. Montone Claire D. James Frederico O. Gleber-Netto Gregory S. Weinstein Jalal Jalaly Alexander Lin Anil K. Rustgi Hiroshi Nakagawa Joseph A. Califano Curtis R. Pickering Elizabeth A. White Bradford E. Windle Iain M. Morgan Roger B. Cohen Phyllis A. Gimotty Devraj Basu 《International journal of cancer. Journal international du cancer》2020,147(11):3236-3249
7.
8.
9.
Julia Thornton Snider Jesse Sussell Mahlet Gizaw Tebeka Alicia Gonzalez Joshua T. Cohen Peter Neumann 《Value in health》2019,22(3):332-339
Background
Payers frequently rely on budget impact model (BIM) results to help determine drug coverage policy and its effect on their bottom line. It is unclear whether BIMs typically overestimate or underestimate real-world budget impact.Objective
We examined how different modeling assumptions influenced the results of 6 BIMs from the Institute for Clinical and Economic Review (ICER).Study Design
Retrospective analysis of pharmaceutical sales data.Methods
From ICER reports issued before 2016, we collected estimates of 3 BIM outputs: aggregate therapy cost (ie, cost to treat the patient population with a particular therapy), therapy uptake, and price. We compared these against real-world estimates that we generated using drug sales data. We considered 2 classes of BIM estimates: those forecasting future uptake of new agents, which assumed “unmanaged uptake,” and those describing the contemporaneous market state (ie, estimates of current, managed uptake and budget impact for compounds already on the market).Results
Differences between ICER's estimates and our own were largest for forecasted studies. Here, ICER's uptake estimates exceeded real-world estimates by factors ranging from 7.4 (sacubitril/valsartan) to 54 (hepatitis C treatments). The “unmanaged uptake” assumption (removed from ICER's approach in 2017) yields large deviations between BIM estimates and real-world consumption. Nevertheless, in some cases, ICER's BIMs that relied on current market estimates also deviated substantially from real-world sales data.Conclusions
This study highlights challenges with forecasting budget impact. In particular, assumptions about uptake and data source selection can greatly influence the accuracy of results. 相似文献10.
Julia H. Vermylen Gordon J. Wood Elaine R. Cohen Jeffrey H. Barsuk William C. McGaghie Diane B. Wayne 《Journal of pain and symptom management》2019,57(3):682-687